Scienmag

MAY 17, 2022

These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts.

Production 90

Production Insulin Development DNA 90

Pharmaceutical Technology

JUNE 8, 2023

GenScript ProBio has collaborated with the New York Blood Center Enterprises’ business unit, called Comprehensive Cell Solutions (CCS), to accelerate the development and manufacture of cell and gene therapies. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

BioTech 365

SEPTEMBER 20, 2021

Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & Reagents), Technique (Promoter Analysis, RNA Exp.) – ResearchAndMarkets.com Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & … Continue reading → (..)

Gene Expression 40

Gene Expression Reagent DNA RNA 40

Drug Discovery World

NOVEMBER 23, 2022

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Pharmaceutical Technology

MARCH 28, 2023

Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. The gene-editing technology allows for precise, directed changes to genomic DNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Drug Discovery World

NOVEMBER 29, 2022

Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. . The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at lower cost. .

DNA 52

DNA Development Research Drugs 52

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. Astera Software: Astera API Management The new product is a no-code, automated, unified platform for complete API lifecycle management and integrations.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

OCTOBER 10, 2022

By Dr Dina Finan, PhD, Product Manager at 10x Genomics and Dr Nick Downey, PhD, NGS Collaborations Lead at Integrated DNA Technologies. The post Is single-cell gene expression the next trend in next generation sequencing? To read this content in full, you need to login. Not yet a DDW member? Username or E-mail. Remember Me.

Gene Expression 98

Gene Expression Gene RNA DNA 98

BioTech 365

DECEMBER 10, 2020

Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments — Complete Gene Offering Improved Efficiency for Customers — SOUTH SAN FRANCISCO, Calif.–(BUSINESS

Gene 52

Gene Production DNA 52

Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. Why are those important?

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Pharmaceutical Technology

DECEMBER 8, 2022

Developing neoantigen products needed for the therapy has faced difficulties including lead time to get GMP DNA and complicated supply chains. With a five-day manufacturing process, the enzymatic production approach of Touchlight will back Odimma in developing its programme. .

DNA 147

DNA Genetics Manufacturing Production 147

Drug Discovery World

MAY 16, 2023

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. NewBiologix is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies.

Production 52

Production Gene Therapy Gene Bioinformatics 52

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. Both gene therapies are approved for individuals 12 years of age and older with sickle cell disease. It also affects Hispanic Americans, but at a lower prevalence.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Drug Discovery World

MAY 7, 2024

Where the bottlenecks of achieving higher cell density and higher titers were once thought to be issues of the past, hurdles have now shifted to achieving speed and scale in mAb production without sacrificing quality. DC: Antibodies have and remain a large product class within the biopharmaceutical market.

Antibody 59

Antibody Production Manufacturing Engineer 59

Drug Discovery World

OCTOBER 24, 2022

This free webinar, hosted by DDW and supported by Catalent, will be presented by Matthias Craig, Senior Manager Product Development, Catalent. You will learn: Key considerations during plasmid production including design and screening systems, processing, and analytical testing. Register for free. Register for free. .

Production 40

Production Gene Therapy DNA Gene 40

STAT News

APRIL 17, 2023

Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint. Pigs that are less likely to induce allergic reactions in humans.

Genome 98

Genome Genomics Genetic Engineering Production 98

Worldwide Clinical Trials

JUNE 15, 2022

At the end of May, we hosted a webinar titled “ Changing Times, Changing Therapies: Keeping Up with Advancements in Cell and Gene Therapies ” to provide a quick update on the latest advancements and ongoing in development of these advanced therapeutics. Clinical holds are becoming more common, especially in gene therapy programs.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. Many scientists are now discovering that this junk DNA plays an essential role in our biology and the epigenetic processes that respond to the environment to drive disease.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

APRIL 22, 2022

Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three gene therapy candidates for Duchenne muscular dystrophy in preclinical development. The post Astellas takes $170m charge as it drops DMD gene therapies appeared first on.

Gene Therapy 105

Gene Therapy Gene DNA Licensing 105

Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. Why are those important?

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Pharma Mirror

FEBRUARY 23, 2021

Together, the addition of pDNA technology and production capabilities. SOMERSET, N.J. SOMERSET, N.J. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility.

Genetics 130

Genetics Manufacturing Gene Therapy DNA 130

BioPharma Reporter

MAY 18, 2021

Charles River Laboratories International, Inc is to acquire US based Vigene Biosciences, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions for research and clinical applications.

DNA 52

DNA Gene Therapy Production Gene 52

BioTech 365

AUGUST 17, 2020

– Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA™ Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA – STONY BROOK, N.Y.–(BUSINESS

DNA 40

DNA Gene Gene Therapy Manufacturing 40

Medical Xpress

FEBRUARY 9, 2023

When cells copy DNA to produce RNA transcripts, they include only some chunks of genetic material known as exons and throw out the rest. The resulting product is a fully-mature RNA molecule, which can be used as a template to build a protein.

RNA 75

RNA DNA Gene Genetics 75

BioTech 365

SEPTEMBER 18, 2020

DUBLIN–(BUSINESS WIRE)–The “Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027” report has been added to ResearchAndMarkets.com’s offering.

DNA 40

DNA Engineer Gene Marketing 40

Drug Discovery Today

JANUARY 13, 2020

The novel silicon chip is a key component of Evonetix’s desktop DNA platform which, once fully developed, will facilitate and enable the rapidly growing field of synthetic biology.

DNA 40

DNA Production Gene Manufacturing 40

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccination 289

Vaccination Vaccine Gene Therapy Manufacturing 289

Pharmaceutical Technology

MAY 17, 2023

AGC Biologics has introduced the BravoAAV and ProntoLVV viral vector platforms that offer quick clinical and commercial production and release of good manufacturing practices (GMP). The new platforms have production at various scales in suspension and adhesion up to 2,000l and 750l, respectively.

Gene Therapy 130

Gene Therapy Gene Manufacturing Production 130

BioTech 365

OCTOBER 28, 2020

DUBLIN–(BUSINESS WIRE)–The “Viral Vector and Plasmid DNA Manufacturing Market – Growth, Trends, and Forecasts (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering.

DNA 40

DNA Manufacturing Gene Therapy Marketing 40

Drug Discovery World

SEPTEMBER 25, 2023

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.

Genome 52

Genome Genomics Gene Editing Medicine 52

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 40

Licensing Licensing Manufacturing Gene 40

Drug Discovery World

NOVEMBER 14, 2022

Don’t forget to register for this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. You will learn: Key considerations during plasmid production including design and screening systems, processing, and analytical testing.

Gene Therapy 52

Gene Therapy DNA Gene Manufacturing 52

Drug Discovery World

NOVEMBER 7, 2022

Register now to attend this free webinar, hosted by DDW and supported by Catalent, which will be presented by Matthias Craig, Senior Manager Product Development, Catalent. You will learn: Key considerations during plasmid production including design and screening systems, processing, and analytical testing. Register for free.

Gene Therapy 52

Gene Therapy DNA Gene Manufacturing 52

Drug Discovery World

NOVEMBER 4, 2022

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. . It will take place on November 17, 2022, 3pm GMT, 4pm CET.

Gene Therapy 52

Gene Therapy DNA Gene Manufacturing 52

Drug Discovery World

OCTOBER 31, 2022

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. . It will take place on November 17, 2022, 3pm GMT, 4pm CET.

Manufacturing 52

Manufacturing Gene Therapy DNA Gene 52

Drug Discovery World

OCTOBER 17, 2022

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. . It will take place on November 17, 2022, 3pm GMT, 4pm CET.

Gene Therapy 52

Gene Therapy DNA Gene Manufacturing 52

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52